NovoCure Limited (NVCR)
Nasdaq · Healthcare · Medical Devices
$15.20+1.74%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.8B
- 52-week range
- $9.82 – $21.45
- 52-week change
- +3.03%
- EPS (trailing)
- −$1.30
- Analyst rating
- 2.0 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $655M (+8.28%)
- Net income
- −$136M
- Operating margin
- −23.5%
- Diluted EPS
- −$1.22
- Free cash flow
- −$75.7M
From the company’s annual report on SEC EDGAR.
About NovoCure Limited
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Headquarters: Baar, Switzerland · 1,605 employees · novocure.com